Currently Viewing:
American Society of Hematology Annual Meeting & Exposition
Research to Look Out for at ASH 2018
November 26, 2018
Real-World Evidence With Axicabtagene Ciloleucel CAR T Treatment Similar to ZUMA-1 Trial Findings
December 01, 2018
Studies at ASH Evaluate Episodic ED Utilization, Adherence, QOL in Sickle Cell Disease
December 01, 2018
Dr Theresa Keegan: AYAs Continue to Be Underrepresented in Clinical Trials
December 01, 2018
Dr Elizabeth Griffiths: Mutational Data Help Inform Clinical Prognosis, Treatment Protocol in AML
December 01, 2018
Length of Hospital Stay Key Driver of Costs Associated With CRS Following CAR T Treatment
December 02, 2018
Dr Jeff Sharman Discusses Standard of Care for CLL Based on Treatment Setting
December 03, 2018
Dr Alison Moskowitz on the Importance of Patients Understanding Their Diagnosis, Treatment Options
December 03, 2018
Ibrutinib Alone Better Than Chemoimmunotherapy as Frontline in Older Patients With CLL
December 03, 2018
ASH-EHA Joint Symposium Dives Deep Into the Leukemia–Down Syndrome Connection
December 03, 2018
iLLUMINATE: Superior PFS With Ibrutinib–Obinutuzumab Even in High-Risk, Untreated CLL/SLL
December 03, 2018
Dr Irene Roberts on Increased Risk of Leukemia in Patients With Down Syndrome
December 03, 2018
Dr Robert Rifkin Outlines Recent Treatment Advances in Multiple Myeloma
December 03, 2018
NCI Director Highlights a Year of Progress in Hematology, Outlines Areas of Focus Going Forward
December 18, 2018
Dr Jeff Sharman: Cost of Therapy Is a Major Challenge in CLL
January 06, 2019
Dr Theresa Keegan on Barriers, Facilitators to Clinical Trial Participation Among AYAs
January 07, 2019
Dr Jennifer Brown on the Role of Genomic Sequencing in CLL
January 08, 2019
Currently Reading
Dr Robert Rifkin Discusses Barriers, Biomarkers in Multiple Myeloma
January 10, 2019

Dr Robert Rifkin Discusses Barriers, Biomarkers in Multiple Myeloma

The biggest barrier to positive clinical outcomes in multiple myeloma is access, explained Robert Rifkin, MD, FACP, medical director, biosimilars and associate chair, hematology research, McKesson Specialty Health.


The biggest barrier to positive clinical outcomes in multiple myeloma is access, explained Robert Rifkin, MD, FACP, medical director, biosimilars and associate chair, hematology research, McKesson Specialty Health.

Transcript

What are the biggest barriers to positive clinical outcomes in multiple myeloma?


I think the barriers are interesting. Certainly, one of them is going to be access. So, there’s a lot being done to improve access to minorities. There’s a whole demographic out there about multiple myeloma in African Americans, and when you slice through all of the data, perhaps the biggest barrier to good outcomes is access to clinical care. So, within the myeloma community, there’s a large effort to see if we can erase that and make things readily available to everyone.

What biomarkers guide treatment protocol in multiple myeloma?

With multiple myeloma, we’re actually in a unique era. Before we used to just stage patients and sort of determine treatment based on stage. Now, it’s considerably more complicated with that, and we’re starting and continuing to do risk stratification, and there’s a lot of debate about who is high risk and who is not. And then I think in this day and age, we’re very fortunate in that we have a lot of agents to pick from and we have a lot of frail elderly multiple myeloma patients where you can now sort of design a very nice regimen that will be effective and well tolerated. So, I think the barriers are really the racial minority barrier and then also finding stuff that we can treat elderly and frail patients with because myeloma is still a disease of the elderly.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up